Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand caucasian population: a case-control study
© Ferguson et al; licensee BioMed Central Ltd. 2009
Received: 20 August 2008
Accepted: 27 March 2009
Published: 27 March 2009
The nucleotide-binding oligomerization domain containing 1 (NOD1) gene encodes a pattern recognition receptor that senses pathogens, leading to downstream responses characteristic of innate immunity. We investigated the role of NOD1 single nucleotide polymorphisms (SNPs) on IBD risk in a New Zealand Caucasian population, and studied Nod1 expression in response to bacterial invasion in the Caco2 cell line.
DNA samples from 388 Crohn's disease (CD), 405 ulcerative colitis (UC), 27 indeterminate colitis patients and 201 randomly selected controls, from Canterbury, New Zealand were screened for 3 common SNPs in NOD1, using the MassARRAY® iPLEX Gold assay. Transcriptional activation of the protein produced by NOD1 (Nod1) was studied after infection of Caco2 cells with Escherichia coli LF82. Carrying the rs2075818 G allele decreased the risk of CD (OR = 0.66, 95% CI = 0.50–0.88, p < 0.002) but not UC. There was an increased frequency of the three SNP (rs2075818, rs2075822, rs2907748) haplotype, CTG (p = 0.004) and a decreased frequency of the GTG haplotype (p = 0.02).in CD. The rs2075822 CT or TT genotypes were at an increased frequency (genotype p value = 0.02), while the rs2907748 AA or AG genotypes showed decreased frequencies in UC (p = 0.04), but not in CD. Functional assays showed that Nod1 is produced 6 hours after bacterial invasion of the Caco2 cell line.
The NOD1 gene is important in signalling invasion of colonic cells by pathogenic bacteria, indicative of its' key role in innate immunity. Carrying specific SNPs in this gene significantly modifies the risk of CD and/or UC in a New Zealand Caucasian population.
Pathogens are sensed by pattern recognition receptors (PRRs), including cytosolic nucleotide oligomerisation domain (Nod) proteins, resulting in downstream responses involving the activation of transcription factors and the induction of apoptosis genes. Intestinal epithelial cells are among several cell types that express such proteins, including Nod1 and Nod 2 .
Since initial publications claiming that single nucleotide polymorphisms (SNPs) in NOD2 provide a major risk factor for CD [2, 3], there have been many reports of other susceptibility alleles . Nod2 recognizes a range of bacteria through a cell wall peptidoglycan. However, the related Nod1 may be even more important, since it senses a wider range of pathogens. In epithelial cells, Nod1 appears to be indispensable for sensing of intracellular gram-negative bacteria .
The NOD 1 gene (MIM# 605980) is located on chromosome 7p14.3. An initial study reported no relationship between SNPs in NOD1 and risk of IBD in European patients . However, McGovern and co-workers  pointed out that the SNP tested was a rare variant, and that the risk of complex diseases is associated with regulatory mutations that occur commonly in a population. These authors reported an association between a complex insertion/deletion polymorphism in NOD1 and susceptibility to CD in a European population. However, although Canto et al,  found similar results in their Spanish subjects, several other studies have failed to replicate this finding in other European populations [8–10]. Although the main focus of the original McGovern et al.,  paper was on the complex deletion, associations were also observed between IBD and several other SNPs, including NOD1 c.156C>G (P < 0.02) and g27606C>T, (P < 0.05). They also reported an association with haplotypes containing g.45343G>A.
SNPs in the genes for three different pattern recognition receptors (NOD2, DLG5 and TLR4) have been previously associated with CD in the New Zealand population [11–13]. Here we consider the implications of three different NOD1 SNPs for their effects on IBD susceptibility in a Caucasian population from the Canterbury region of New Zealand. We also consider the functional role of Nod1 in relation to invasion of the gastrointestinal colon cell line, Caco2 by the CD-associated bacterium, Escherichia coli LF82 .
Case control study
NOD1 polymorphisms tested in the Canterbury population
0.869 (n = 214)
0.706 (n = 92)
0.735 (n = 200)
Summary of clinical and demographic data for the set of Caucasian IBD patients
Age at first diagnosis
Between 17 and 40
Non-stricturing, non-penetrating perianal disease
Stricturing perianal disease
Penetrating perianal disease
Any relative with IBD: Yes (n = 143)
Bowel resection: Yes (n = 214)
Smoker at diagnosis: Yes (n = 147)
Ever used immunomodulators: Yes (n = 296)
Extraintestinal manifestations: Yes (n = 142)
Genotype and allele counts for NOD1/CARD4 variants in New Zealand IBD patients and in New Zealand Caucasians
OR (95% CI)
OR (95% CI)
OR (95% CI)
Carrying the NOD1 g.27606C>T variant led to statistically significant changes in the probability of developing UC, but not CD (Table 3). The CT heterozygote had a 2.65-fold (OR = 2.65, 95% CI = 1.29–5.41) greater risk, while TT homozygotes had a 2.45-fold (OR = 2.45, 95% CI = 1.23–4.85) greater risk of developing the disease, as compared with the risk for CC homozygotes (p = 0.02). For g.45343G>A SNP, it is the major allele that carries the increased risk. AG heterozygotes (OR = 2.32, 95% CI = 1.18–4.53) and GG homozygotes (OR = 2.19, 95% CI = 1.14–4.22) have an increased risk of developing the disease, as compared with AA homozygotes (p = 0.04). There was no significant difference in the allele frequencies between control subjects and CD, UC, or IBD patients (Table 3).
Allelic odds ratios and 95% confidence intervals for comparison of NOD1/CARD4 variants with IBD status in New Zealand IBD patients and Caucasians
Allelic odds ratios and 95% confidence intervals for comparison of NOD1 rs2075818
Allelic odds ratios and 95% confidence intervals for comparison of NOD1 rs2075822
Allelic odds ratios and 95% confidence intervals for comparison of NOD1 rs2907748
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
Age at first diagnosis
Any relative with IBD
Smoker at diagnosis
Ever used immunomodulators
Haplotype analysis of three-SNP NOD1 haplotype in IBD patients and Caucasians in a New Zealand population.
Case subject frequency (%)
Control subject frequency (%)
OR (95% CI)
Global score statistics
Three SNPs NOD1gregion
(rs2075818, rs2075822, rs2907748)
χ2 = 9.55,
df = 3,
p = 0.02
Three SNPs NOD1gregion
(rs2075818, rs2075822, rs2907748)
χ2 = 2.30,
df = 3,
p = 0.51
These haplotypes differed significantly between CD patients and control subjects (χ2 = 9.55, df = 3, p = 0.02) (Table 5). Haplotype CTG frequencies in cases was 55.8% and in controls 46.9% (p = 0.004). The frequencies of haplotype GTG were 16.0% and 21.7% for CD case and control subjects respectively (p = 0.02). Haplotypes CCG, CTA, GCA, and GCG were the most uncommon in CD cases and control subjects, and occurred at equal frequencies in the two groups (p > 0.05). There were no significant associations between these haplotypes for UC cases as compared with control subjects (χ2 = 2.30, df = 3, p = 0.51). Haplotype CTG was the most common in UC cases but occurred at equal frequencies between UC case and control subjects (p > 0.05).
Crohn's disease-associated Escherichia coli LF82 leads to the transcriptional activation of Nod1
The present study adds to a growing database supporting a role for pattern recognition receptors ininflammatory bowel diseases . Previous data associating NOD1 polymorphisms with IBD risk showed variable results. Zouali, et al., , with European subjects, and Ozen et al.,  with Turkish patients, concluded that NOD1 was not involved in IBD. However, subject numbers in both studies were small. Molnar et al.,  reported that the E266K (c.796G>A) NOD1 polymorphism was associated with disease susceptibility but not with disease phenotype or NOD 2 or TLR4 polymorphisms in Hungarian patients with CD.
Following the very strongly positive associations reported by McGovern et al., , most of the more recent publications have focussed on the complex (ND(1)+32656*) NOD1 deletion mutation. Canto et al,  reported that the distribution of the NOD1 polymorphism in patients was different from controls, and not altered by the existence of NOD2 mutations in their Spanish population. However, Van Limbergen et al, [10, 17] showed no statistically significant differences in frequency of this variant between cases and controls in large Scottish or Swedish populations. Similar results were reported by Franke et al.,  (German subjects) and Tremelling et al.,  (East Anglian subjects).
We are not certain of the functionality of the SNPs in the present study. We note that the insertion-deletion polymorphism (ND(1)+32656) that has given such variable results in IBD population studies accounted for approximately 7% of the variation in IgE in two panels of families (P < 0.0005 in each). That is, there is in vivo evidence for functionality. According to our data the infection of Caco2 cells with the adherent-invasive Escherichia coli (AIEC) strain LF82 leads to the transcriptional activation of Nod1. AIEC strains have been specifically associated with CD ileal mucosa with a prevalence of 36.4% .
Taken together, these data may suggest that NOD1 plays a variable role in different populations that could depend upon environmental and dietary factors. The gene may be especially important in Caucasian groups within New Zealand
Participants and genotyping
Cases for this study were provided through the Canterbury Inflammatory Bowel Disease Project, and controls randomly selected from a population-based cohort, both of which are described more fully elsewhere [20, 21]. Both CD and UC were defined using standard diagnostic criteria, and cases phenotyped according to the Montreal Classification systems .
This study had ethical approval from the Canterbury Ethics Committee and the Southern Regional Health Authority's Ethics Committee in Canterbury, New Zealand, and all participants gave their written informed consent.
Primer and probe sequences for custom made Sequenom SNP genotyping assay for NOD1
To estimate genotype accuracy, approximately 12% of the samples were genotyped in duplicate or triplicate. We estimated the error rate to be <1%.
Bacterial strain and culture conditions for functional assays
E. coli strain LF82, isolated from a chronic ileal lesion of a French patient with CD, was a kind gift of A. Darfeuille-Michaud, Université Clermont I, Pathogénie Bactérienne Intestinale, Clermont-Ferrand, France. Bacteria were grown routinely in Luria-Bertani (LB) broth or on LB agar plates overnight at 37°C.
Cell culture and infection protocol
The human colorectal cancer cell line Caco-2 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco's modified Eagle medium (DMEM) with L-glutamine supplemented with 10% heat-inactivated fetal calf serum (Moregate, Hamilton, New Zealand), 1 mM sodium pyruvate and 1 mM non essential amino acids. All reagents were supplied from Invitrogen, Auckland, New Zealand. Cultures were maintained at 37°C in a humidified 5% CO2 atmosphere. Monolayers were seeded in 24-well tissue culture plates (BD, Bioscience, Auckland, New Zealand) with 2 × 105 cells/well and incubated for 14 days. During this time the cell medium was constantly replenished.
For infection experiments, bacteria were grown overnight in LB broth at 37°C. Before starting the infection the cell monolayers were washed twice with phosphate-buffered saline (PBS, pH 7.2). Each monolayer was infected in 1 ml of the cell culture medium without FCS at a multiplicity of infection (MOI) of 10 bacteria per epithelial cell. After a 6-h and 9-h incubation period at 37°C with 10% CO2, infected monolayers were washed three times with PBS and the cells were trypsinated with 10% Trypsin-EDTA (Invitrogen, Auckland, New Zealand). To remove the trypsin cells were centrifuged for 1 min at 1500 rpm and the cell pellets were stored at -80°C.
RNA isolation and RT-PCR
Total RNA was extracted from non-infected and infected Caco2 cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) following manufacturer's protocols. The RNA was quantified spectrophotometrically and then stored at -80°C. Reverse transcription of 1.5 μg of total RNA to complementary DNA (cDNA) was carried out using the SuperScript™III First-strand Synthesis – Super Mix Kit (Invitrogen, Auckland, New Zealand) and oligo(dT)20 primers, according to the standard protocol. The primers used for PCR had the following sequences: NF-κB, 5'-ACAAATGGGCTACACCGAAG-3', 5'-GGACAACGCAGTGGAATTTT-3'; Nod1, 5'-AGCTGAAGATGAATTTGGGAAA-3', 5'-GCCGAGAAGTAGTCATTCTTCAG-3' and Actin 5'-CATTGCCGACAGGATGCA-3', 5'-CCGATCCACACGGAGTACTTG-3'. These sets of primers yield to PCR products that were 198 bp (Nod1), 341 bp (NF-κB) and 102 bp (Actin) long, respectively. Results are expressed as the relative mRNA accumulation corrected using Actin mRNA as an internal standard.
The allelic trend test  and Fisher's exact genotypic test were used to compare case and control allele frequencies. An exact test was used to test for departures from Hardy-Weinberg equilibrium (HWE) in the case and the control samples . Allelic odds ratios were calculated and confidence intervals for the allelic odds ratio were also calculated under the assumption of HWE in the cases and the control groups. Logistic regression analysis was used for subgroup analysis. Other analyses were carried out using R , SHEsis  (available from http://analysis.bio-x.cn/myAnalysis.php), and SAS (V9.1 SAS Institute., Cary, NC, USA).
caspase-activated recruitment domain
nucleotide oligomerisation domain
pattern recognition receptors
Single Nucleotide Polymorphism
We thank Rebecca Roberts for help preparing the DNA plates, Ivonne Petermann for help with designing the primers, and the Canterbury participants in our study. Other funding sources for the case and control DNA collection are the Canterbury Medical Research Foundation and Canterbury Liver and Digestive Diseases Trust. Nutrigenomics New Zealand is a collaboration between AgResearch Ltd., Crop & Food Research, HortResearch and The University of Auckland, with funding through the Foundation for Research Science and Technology.
- Hruz P, Eckmann L: Caspase recruitment domain-containing sensors and adaptors in intestinal innate immunity. Curr. 2008, 24 (2): 108-114.Google Scholar
- Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, et al: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. [see comment]. Nature. 2001, 411 (6837): 603-606. 10.1038/35079114.View ArticlePubMedGoogle Scholar
- Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, et al: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. [see comment]. Nature. 2001, 411 (6837): 599-603. 10.1038/35079107.View ArticlePubMedGoogle Scholar
- Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, et al: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008, 40 (8): 955-962. 10.1038/ng.175.PubMed CentralView ArticlePubMedGoogle Scholar
- Zouali H, Lesage S, Merlin F, Cezard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O'Morain C, Gassull M, et al: CARD4/NOD1 is not involved in inflammatory bowel disease. Gut. 2003, 52 (1): 71-74. 10.1136/gut.52.1.71.PubMed CentralView ArticlePubMedGoogle Scholar
- McGovern DP, Hysi P, Ahmad T, van Heel DA, Moffatt MF, Carey A, Cookson WO, Jewell DP: Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet. 2005, 14 (10): 1245-1250. 10.1093/hmg/ddi135.View ArticlePubMedGoogle Scholar
- Canto E, Ricart E, Busquets D, Monfort D, Garcia-Planella E, Gonzalez D, Balanzo J, Rodriguez-Sanchez JL, Vidal S: Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype. World J Gastroenterol. 2007, 13 (41): 5446-5453.PubMed CentralView ArticlePubMedGoogle Scholar
- Franke A, Ruether A, Wedemeyer N, Karlsen TH, Nebel A, Schreiber S: No association between the functional CARD4 insertion/deletion polymorphism and inflammatory bowel diseases in the German population. Gut. 2006, 55 (11): 1679-1680. 10.1136/gut.2006.104646.PubMed CentralView ArticlePubMedGoogle Scholar
- Tremelling M, Hancock L, Bredin F, Sharpstone D, Bingham SA, Parkes M: Complex insertion/deletion polymorphism in NOD1 (CARD4) is not associated with inflammatory bowel disease susceptibility in East Anglia panel. Inflamm Bowel Dis. 2006, 12 (10): 967-971. 10.1097/01.mib.0000234131.89971.e5.View ArticlePubMedGoogle Scholar
- Van Limbergen J, Nimmo ER, Russell RK, Drummond HE, Smith L, Anderson NH, Davies G, Arnott ID, Wilson DC, Satsangi J: Investigation of NOD1/CARD4 variation in inflammatory bowel disease using a haplotype-tagging strategy. Hum Mol Genet. 2007, 16 (18): 2175-2186. 10.1093/hmg/ddm169.View ArticlePubMedGoogle Scholar
- Gearry RB, Roberts RL, Burt MJ, Frampton CM, Chapman BA, Collett JA, Shirley P, Allington MD, Kennedy MA, Barclay ML: Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflamm Bowel Dis. 2007, 13 (10): 1220-1227. 10.1002/ibd.20190.View ArticlePubMedGoogle Scholar
- Browning BL, Huebner C, Petermann I, Demmers P, McCulloch A, Gearry RB, Barclay ML, Shelling AN, Ferguson LR: Association of DLG5 variants with inflammatory bowel disease in the New Zealand Caucasian population and meta-analysis of the DLG5 R30Q variant. Inflamm Bowel Dis. 2007, 13 (9): 1069-1076. 10.1002/ibd.20157.View ArticlePubMedGoogle Scholar
- Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, Ferguson LR: Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol. 2007, 102 (11): 2504-2512. 10.1111/j.1572-0241.2007.01463.x.View ArticlePubMedGoogle Scholar
- Boudeau J, Glasser AL, Masseret E, Joly B, Darfeuille-Michaud A: Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun. 1999, 67 (9): 4499-4509.PubMed CentralPubMedGoogle Scholar
- Ozen SC, Dagli U, Kilic MY, Toruner M, Celik Y, Ozkan M, Soykan I, Cetinkaya H, Ulker A, Ozden A, et al: NOD2/CARD15, NOD1/CARD4, and ICAM-1 gene polymorphisms in Turkish patients with inflammatory bowel disease. J Gastroenterol. 2006, 41 (4): 304-310. 10.1007/s00535-005-1780-z.View ArticlePubMedGoogle Scholar
- Molnar T, Hofner P, Nagy F, Lakatos PL, Fischer S, Lakatos L, Kovacs A, Altorjay I, Papp M, Palatka K, et al: NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease. Dig Liver Dis. 2007, 39 (12): 1064-1070. 10.1016/j.dld.2007.09.003.View ArticlePubMedGoogle Scholar
- Van Limbergen J, Russell RK, Nimmo ER, Torkvist L, Lees CW, Drummond HE, Smith L, Anderson NH, Gillett PM, McGrogan P, et al: Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern Europe. Inflamm Bowel Dis. 2007, 13 (7): 882-889. 10.1002/ibd.20124.View ArticlePubMedGoogle Scholar
- Hysi P, Kabesch M, Moffatt MF, Schedel M, Carr D, Zhang Y, Boardman B, von Mutius E, Weiland SK, Leupold W, et al: NOD1 variation, immunoglobulin E and asthma. Hum Mol Genet. 2005, 14 (7): 935-941. 10.1093/hmg/ddi087.View ArticlePubMedGoogle Scholar
- Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004, 127 (2): 412-421. 10.1053/j.gastro.2004.04.061.View ArticlePubMedGoogle Scholar
- Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chapman BA, Barclay ML: High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis. 2006, 12 (10): 936-943. 10.1097/01.mib.0000231572.88806.b9.View ArticlePubMedGoogle Scholar
- Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman TM, Walmsley TA, Chapman BA: The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 1998, 43 (6): 830-836.PubMed CentralView ArticlePubMedGoogle Scholar
- Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, et al: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005, 19 (Suppl A): 5-36.Google Scholar
- Leushner J, Chiu NH: Automated mass spectrometry: a revolutionary technology for clinical diagnostics. Mol Diagn. 2000, 5 (4): 341-348.View ArticlePubMedGoogle Scholar
- Bray MS, Boerwinkle E, Doris PA: High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise. Hum Mutat. 2001, 17 (4): 296-304. 10.1002/humu.27.View ArticlePubMedGoogle Scholar
- Sasieni PD: From genotypes to genes: doubling the sample size. Biometrics. 1997, 53 (4): 1253-1261. 10.2307/2533494.View ArticlePubMedGoogle Scholar
- Wigginton JE, Cutler DJ, Abecasis GR: A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet. 2005, 76 (5): 887-893. 10.1086/429864.PubMed CentralView ArticlePubMedGoogle Scholar
- Ihaka R, Gentleman R: R: A language for data analysis and graphics. Journal of Computational and Graphical Statistics. 1996, 5 (3): 299-314. 10.2307/1390807.Google Scholar
- Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15 (2): 97-98. 10.1038/sj.cr.7290272.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.